Parker S - Search Results

1

Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice.

Quenelle DC, Buller RM, Parker S, Keith KA, Hruby DE, Jordan R, Kern ER. Quenelle DC, et al. Among authors: parker s. Antimicrob Agents Chemother. 2007 Feb;51(2):689-95. doi: 10.1128/AAC.00879-06. Epub 2006 Nov 20. Antimicrob Agents Chemother. 2007. PMID: 17116683 Free PMC article.

2

Evaluation of disease and viral biomarkers as triggers for therapeutic intervention in respiratory mousepox - an animal model of smallpox.

Parker S, Chen NG, Foster S, Hartzler H, Hembrador E, Hruby D, Jordan R, Lanier R, Painter G, Painter W, Sagartz JE, Schriewer J, Mark Buller R. Parker S, et al. Antiviral Res. 2012 Apr;94(1):44-53. doi: 10.1016/j.antiviral.2012.02.005. Epub 2012 Feb 18. Antiviral Res. 2012. PMID: 22381921 Free PMC article.

3

The attenuated NYCBH vaccinia virus deleted for the immune evasion gene, E3L, completely protects mice against heterologous challenge with ectromelia virus.

Denzler KL, Schriewer J, Parker S, Werner C, Hartzler H, Hembrador E, Huynh T, Holechek S, Buller RM, Jacobs BL. Denzler KL, et al. Among authors: parker s. Vaccine. 2011 Dec 6;29(52):9691-6. doi: 10.1016/j.vaccine.2011.09.108. Epub 2011 Oct 5. Vaccine. 2011. PMID: 21983358 Free PMC article.

4

A human recombinant analogue to plasma-derived vaccinia immunoglobulin prophylactically and therapeutically protects against lethal orthopoxvirus challenge.

Parker S, D'Angelo J, Buller RM, Smee DF, Lantto J, Nielsen H, Jensen A, Prichard M, George SL. Parker S, et al. Antiviral Res. 2021 Nov;195:105179. doi: 10.1016/j.antiviral.2021.105179. Epub 2021 Sep 13. Antiviral Res. 2021. PMID: 34530009 Free PMC article.

5

The Virology of Taterapox Virus In Vitro.

Parker S, Camilo de Oliveira L, Lefkowitz EJ, Hendrickson RC, Bonjardim CA, Wold WSM, Hartzler H, Crump R, Buller RM. Parker S, et al. Viruses. 2018 Aug 29;10(9):463. doi: 10.3390/v10090463. Viruses. 2018. PMID: 30158437 Free PMC article.

6

Evaluation of Taterapox Virus in Small Animals.

Parker S, Crump R, Hartzler H, Buller RM. Parker S, et al. Viruses. 2017 Aug 1;9(8):203. doi: 10.3390/v9080203. Viruses. 2017. PMID: 28763036 Free PMC article.

7

A mouse model of lethal infection for evaluating prophylactics and therapeutics against Monkeypox virus.

Stabenow J, Buller RM, Schriewer J, West C, Sagartz JE, Parker S. Stabenow J, et al. Among authors: parker s. J Virol. 2010 Apr;84(8):3909-20. doi: 10.1128/JVI.02012-09. Epub 2010 Feb 3. J Virol. 2010. PMID: 20130052 Free PMC article.

8

Efficacy of therapeutic intervention with an oral ether-lipid analogue of cidofovir (CMX001) in a lethal mousepox model.

Parker S, Touchette E, Oberle C, Almond M, Robertson A, Trost LC, Lampert B, Painter G, Buller RM. Parker S, et al. Antiviral Res. 2008 Jan;77(1):39-49. doi: 10.1016/j.antiviral.2007.08.003. Epub 2007 Sep 4. Antiviral Res. 2008. PMID: 17904231 Free PMC article.

9

Poxvirus interleukin-4 expression overcomes inherent resistance and vaccine-induced immunity: pathogenesis, prophylaxis, and antiviral therapy.

Chen N, Bellone CJ, Schriewer J, Owens G, Fredrickson T, Parker S, Buller RM. Chen N, et al. Among authors: parker s. Virology. 2011 Jan 20;409(2):328-37. doi: 10.1016/j.virol.2010.10.021. Epub 2010 Nov 10. Virology. 2011. PMID: 21071055 Free PMC article.

10

Induction of natural killer cell responses by ectromelia virus controls infection.

Parker AK, Parker S, Yokoyama WM, Corbett JA, Buller RM. Parker AK, et al. Among authors: parker s. J Virol. 2007 Apr;81(8):4070-9. doi: 10.1128/JVI.02061-06. Epub 2007 Feb 7. J Virol. 2007. PMID: 17287257 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

3,173 results

Search Page

Filters